RNAC Q2 2024 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+537.2% YoY

Gross Profit

$33M100.0% margin

Operating Income

$14M41.1% margin

Net Income

$14M41.4% margin

EPS (Diluted)

$0.54

QoQ Revenue Growth

+472.7%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$348M

Total Liabilities

$449M

Stockholders' Equity

-$101M

Cash & Equivalents

$87M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$5M	+537.2%
Gross Profit	$33M	-$13M	+366.9%
Operating Income	$14M	-$19M	+173.8%
Net Income	$14M	-$11M	+221.5%